Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P) - PubMed (original) (raw)
Clinical Trial
. 2018 Jun;178(6):1315-1323.
doi: 10.1111/bjd.16426. Epub 2018 May 15.
Affiliations
- PMID: 29405255
- DOI: 10.1111/bjd.16426
Clinical Trial
Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)
R G Langley et al. Br J Dermatol. 2018 Jun.
Abstract
Background: Ixekizumab is an interleukin-17A antagonist approved for treatment of moderate-to-severe plaque psoriasis with a recommended 160-mg starting dose, then 80 mg every 2 weeks (Q2W) to week 12, and every 4 weeks (Q4W) thereafter.
Objective: To evaluate continuous Q2W dosing over 52 weeks.
Methods: In this phase III, multicentre, double-blinded, parallel-group trial, three ixekizumab dosing regimens were assessed for efficacy and safety at week 52 in patients with moderate-to-severe plaque psoriasis randomized at a 2 : 1 : 1 ratio to continuous Q2W (n = 611), continuous Q4W (n = 310) or dose adjustment per protocol (Q4W/Q2W, n = 306), each with a 160-mg starting dose. Dose adjustment was determined by predefined criteria to which investigators were blinded; 72 (23?5%) patients in the Q4W/Q2W group adjusted dose. Efficacy outcomes were evaluated using logistic regression.
Results: Co-primary end points were met at week 52: Psoriasis Area and Severity Index 75 responses for Q2W and Q4W dose groups were 85·9% and 79·0%, respectively (P = 0·006), and static patient global assessment 0/1 responses for Q2W and Q4W dose groups were 78·6% and 70·6%, respectively (P = 0·005). Treatment-emergent and serious adverse events were comparable across dose groups.
Conclusions: Ixekizumab Q2W had higher efficacy at week 52 than ixekizumab Q4W, with no increase in safety events.
© 2018 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Comment in
- Evidence for improving the therapeutic response to ixekizumab: more than just a statistic.
Borghi A. Borghi A. Br J Dermatol. 2018 Jun;178(6):1237-1238. doi: 10.1111/bjd.16653. Br J Dermatol. 2018. PMID: 29897126 No abstract available.
Similar articles
- An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12.
Papp K, Maari C, Cauthen A, Gooderham M, Spelman L, Yamanaka K, Polzer P, Zhang L, Osuntokun O, Augustin M. Papp K, et al. Br J Dermatol. 2020 Jul;183(1):52-59. doi: 10.1111/bjd.18550. Epub 2019 Dec 8. Br J Dermatol. 2020. PMID: 31545506 - Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, Morita A, Goldblum O, Zhang L, Erickson J, Ball S, Rich P. van de Kerkhof P, et al. J Eur Acad Dermatol Venereol. 2017 Mar;31(3):477-482. doi: 10.1111/jdv.14033. Epub 2016 Dec 2. J Eur Acad Dermatol Venereol. 2017. PMID: 27910156 Clinical Trial. - Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study.
Valenzuela F, de la Cruz Fernandez C, Galimberti RL, Gürbüz S, McKean-Matthews M, Goncalves L, Romiti R. Valenzuela F, et al. Actas Dermosifiliogr. 2017 Jul-Aug;108(6):550-563. doi: 10.1016/j.ad.2017.02.005. Epub 2017 Mar 23. Actas Dermosifiliogr. 2017. PMID: 28342534 Clinical Trial. English, Spanish. - Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.
Syed YY. Syed YY. Am J Clin Dermatol. 2017 Feb;18(1):147-158. doi: 10.1007/s40257-017-0254-4. Am J Clin Dermatol. 2017. PMID: 28138946 Review. - Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Vu TT, Gooderham M, Papp K. Vu TT, et al. Expert Rev Clin Pharmacol. 2016 Nov;9(11):1423-1433. doi: 10.1080/17512433.2016.1242409. Epub 2016 Oct 11. Expert Rev Clin Pharmacol. 2016. PMID: 27690669 Review.
Cited by
- Value of PASI90 Versus Merit-Based Incentive Payment System Efficacy Measures.
Hawkes JE, Reis P, Lin CY, Muram T, Eastman WJ. Hawkes JE, et al. J Psoriasis Psoriatic Arthritis. 2022 Jul;7(3):140-149. doi: 10.1177/24755303221082623. Epub 2022 Apr 19. J Psoriasis Psoriatic Arthritis. 2022. PMID: 39296534 Free PMC article. - IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.
Krueger JG, Eyerich K, Kuchroo VK, Ritchlin CT, Abreu MT, Elloso MM, Fourie A, Fakharzadeh S, Sherlock JP, Yang YW, Cua DJ, McInnes IB. Krueger JG, et al. Front Immunol. 2024 Apr 15;15:1331217. doi: 10.3389/fimmu.2024.1331217. eCollection 2024. Front Immunol. 2024. PMID: 38686385 Free PMC article. Review. - Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6. Cochrane Database Syst Rev. 2023. PMID: 37436070 Free PMC article. Review. - Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials.
Smith SD, Stratigos A, Augustin M, Carrascosa JM, Grond S, Riedl E, Xu W, Patel H, Lebwohl M. Smith SD, et al. Dermatol Ther (Heidelb). 2023 Aug;13(8):1773-1787. doi: 10.1007/s13555-023-00966-4. Epub 2023 Jun 23. Dermatol Ther (Heidelb). 2023. PMID: 37351831 Free PMC article. - Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5. Cochrane Database Syst Rev. 2022. PMID: 35603936 Free PMC article. Updated. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous